Egetis Therapeutics AB (publ)
STO:EGTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Egetis Therapeutics AB (publ)
STO:EGTX
|
SE |
|
Adidas AG
XETRA:ADS
|
DE |
|
P
|
Providence Resources Inc
OTC:PVRS
|
US |
|
WPP PLC
LSE:WPP
|
UK |
Egetis Therapeutics AB (publ)
Egetis Therapeutics AB is a pharmaceutical drug development company, which engages in the development of new drugs for treatment of life threatening diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Egetis Therapeutics AB is a pharmaceutical drug development company, which engages in the development of new drugs for treatment of life threatening diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
